Osimertinib, a third-generation EGFR-TKI, was developed to overcome the EGFR-TKI-resistant T790M mutation in the EGFR gene that is frequently acquired during treatments with standard EGFR-TKIs for NSCLC [22,23]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.